RxDoctor Payments Data

Britney Casciello

Family · New Bern, NCNPI 1609448182

Payments from drug & device makers

$7,964in general payments, 2019–2025

Across 495 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$954
  • Medtronic$937
  • Amgen$886
  • Merck$573
  • Novartis$525
  • Sanofi-aventis U.S. LLC$334
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,960100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,964 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$205,015
Medicare patients
998
Services billed
4,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$187,624
EntrestoSacubitril/Valsartan122$99,795
FarxigaDapagliflozin Propanediol109$70,721
JardianceEmpagliflozin73$53,332
Repatha SureclickEvolocumab77$43,292
XareltoRivaroxaban25$23,924
Ranolazine ErRanolazine151$10,854
Repatha SyringeEvolocumab11$9,614
Dabigatran EtexilateDabigatran Etexilate Mesylate28$6,291
Metoprolol Succinate403$4,849
NexletolBempedoic Acid12$4,624
Valsartan74$2,941
Rosuvastatin Calcium202$2,347
Amiodarone Hcl135$1,696
ClopidogrelClopidogrel Bisulfate163$1,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$183$187,624218 claims
NovartisEntresto$525$99,795122 claims
AstraZenecaFarxiga$218$70,721109 claims
Boehringer IngelheimJardiance$305$53,33273 claims
Johnson & JohnsonXarelto$55$23,92425 claims
Esperion Therapeutics, Inc.Nexletol$84$4,62412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →